Reaktion #1100071

ord-23c0a3b0201b491e9456e3b03f934fbf

Reaktionsgleichung

CCC(=O)OC1(c2ccccc2)CCN(C)CC1
PPMP
O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
glucose
CC(=O)C(=O)[O-]
pyruvate
CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(=O)[O-].[K+]
penicilline
CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](NC(=N)N)[C@@H](O)[C@@H]3NC(=N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O
streptomycine
C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)O
Glutamax
O=C=O
CO2
→
CN[C@H]1[C@@H](O[C@@H]2/C3=C/C#C[C@H]4O[C@@]4([C@H]4COC(=O)O4)C#CC3=C[C@H]2OC(=O)c2cccc3c(C)cc(OC)cc23)O[C@H](C)[C@H](O)[C@@H]1O
Neocarzinostatin

Edukte

—
threo-1-phenyl-2-hexadecanoyl-amino-3-morpholino-1-propanol
CCC(=O)OC1(c2ccccc2)CCN(C)CC1
PPMP
O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
glucose
CC(=O)C(=O)[O-]
pyruvate
CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(=O)[O-].[K+]
penicilline
CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](NC(=N)N)[C@@H](O)[C@@H]3NC(=N)N)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O
streptomycine
C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)O
Glutamax
O=C=O
CO2

Reagenzien

Keine

Reaktionsbedingungen

Detaillierte Bedingungen
See reaction.notes.procedure_details.

Aufarbeitung

  1. 1
    TemperaturHuman cervix adenocarcinoma HeLa cells are maintained as exponentially growing monolayers in Dulbecco
  2. 2
    Waschenwash

Vorschrift

Human cervix adenocarcinoma HeLa cells are maintained as exponentially growing monolayers in Dulbecco modified Eagle's minimum essential medium with 4.5 g/l glucose, 0.1 g/l pyruvate, 105 Ul/l penicilline, 0.1 g/l streptomycine, 0.86 g/l Glutamax I and 10% v/v foetal calf serum (37° C., 5% CO2), without or with 5 μM DL-threo-1-phenyl-2-hexadecanoyl-amino-3-morpholino-1-propanol (PPMP) to inhibit Gb3 expression. When present, PPMP is introduced into pre-cultures for at least 6 days prior to cytotoxicity assays and is present for up to drug wash.

Quelle

DOI: 10.6084/m9.figshare.5104873.v1Patent: US07981400B2uspto-grants-2011_07